Journal Article Ahead of print
PubMed: 42348303 DOI: 10.1080/10428194.2026.2687633
Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.
Leuk Lymphoma
Authors: Lauren D Pomerantz, Kari G Rabe, Paul J Hampel, Lindsey E Roeker, Rachel J Bailen, Amber B Koehler, Catherine C Wagner, Amy L Behnken, Jose F Leis, Talal Hilal, Mazie Tsang, Ricardo D Parrondo, Susan M Schwager, Cinthya J Zepeda-Mendoza, Min Shi, Curtis A Hanson, Susan L Slager, Esteban Braggio, Saad J Kenderian, Neil E Kay, Yucai Wang, Sameer A Parikh
Affiliations
- Mayo Clinic Graduate School of Medical Education, Internal Medicine Residency, Rochester, MN, USA.
- Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
- Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
- Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
- Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ, USA.
- Division of Hematology/Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA.
- Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
- Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
- Department of Immunology, Mayo Clinic, Rochester, MN, USA.
MeSH
Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Leukemia, Lymphoid, Sex